The Joe Tippens Protocol
A comprehensive look at the viral alternative cancer research stack — compounds, mechanisms, evidence quality, and what the science actually says.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
📋 On this page
How It Started
One anecdote. Zero clinical trials. A viral movement.
Joe Tippens — The Viral Anecdote
In 2016, Joe Tippens was diagnosed with Stage 4 small cell lung cancer (SCLC) that had metastasized throughout his body. After a veterinarian friend suggested he try fenbendazole — an animal dewormer — Tippens began taking it alongside conventional treatment.
Tippens later reported complete remission and began sharing his story through a blog (MyCANCERstory.rocks) in 2019. The story went viral, particularly in South Korea where fenbendazole sales surged dramatically.
Critical context: Tippens was also receiving conventional cancer treatment (immunotherapy) during this period. His case is a single anecdote — not clinical evidence. Oncologists have noted that spontaneous remissions, while rare, do occur, and attributing his outcome solely to fenbendazole is scientifically unsupported.
The community protocol has since expanded well beyond Tippens' original regimen, with additional compounds added by various practitioners and patient communities. The “expanded stack” described on this page reflects the broader community protocol — not Tippens’ original combination.
8 Compounds in the Protocol
Community-reported compounds and dosing. These are NOT medical recommendations. Doses shown reflect community protocols, not clinical guidelines.
Fenbendazole
Veterinary antiparasitic (Panacur/Safe-Guard). The core compound of the original protocol. Targets microtubules, glucose uptake, and p53 pathways in preclinical studies.
⚠️ NOT FDA-approved for human use
Mebendazole
Human-approved antiparasitic (Vermox). Same drug class as fenbendazole. Some community members substitute it due to existing human safety data for antiparasitic use.
⚠️ FDA-approved for parasites only, NOT cancer
Ivermectin
Antiparasitic with preclinical anticancer signals. Some expanded protocols include it for potential synergy with benzimidazoles.
⚠️ FDA-approved for parasites only, NOT cancer
Vitamin B17 / Amygdalin
Derived from apricot kernels. Extremely controversial — can release cyanide during metabolism. The FDA has banned its sale as a cancer treatment. Multiple poisoning deaths reported.
🚫 FDA BANNED as cancer treatment. Cyanide toxicity risk.
FECO (Full Extract Cannabis Oil)
High-THC cannabis extract (also called RSO/Rick Simpson Oil). Preclinical data on cannabinoid-induced apoptosis. Legal status varies by jurisdiction.
⚠️ NOT FDA-approved. Schedule I federal status (US)
Methylene Blue
Synthetic dye with mitochondrial effects. FDA-approved for methemoglobinemia only. Preclinical data suggests mitochondrial targeting in cancer cells.
⚠️ FDA-approved for methemoglobinemia only
TUDCA
Tauroursodeoxycholic acid — a liver-protective bile acid. Included as hepatoprotective support given that multiple protocol compounds carry hepatotoxicity risk.
⚠️ Sold as supplement. Not FDA-evaluated for this use.
Activated Charcoal
Used as a binder to adsorb toxins and metabolites. Taken away from other compounds to avoid absorbing them. Common in detox protocols.
⚠️ OTC supplement. Can bind medications — timing critical.
How Key Compounds Work (Preclinical Data)
All mechanisms shown are from cell culture and animal studies. None are confirmed in human cancer patients.
Fenbendazole — Triple Mechanism (Dogra 2018)
- Microtubule disruption — Binds β-tubulin, destabilizes cytoskeleton, arrests mitosis
- Glucose uptake inhibition — Downregulates GLUT4 transporters, starves cancer cells of glucose
- p53 reactivation — Stabilizes wild-type p53 tumor suppressor protein, promotes apoptosis
- Proteasome interference — May affect protein degradation pathways in cancer cells
Mebendazole — Shared Benzimidazole Pathways
- Tubulin binding — Same drug class as fenbendazole, similar microtubule disruption
- Angiogenesis inhibition — May reduce new blood vessel formation to tumors (preclinical)
- Hedgehog pathway — Preclinical data suggests inhibition of Hedgehog signaling in some cancers
- Bcl-2 modulation — May shift pro/anti-apoptotic protein balance toward cell death
Ivermectin — Preclinical Anticancer Signals
- WNT/TCF pathway — May inhibit WNT signaling involved in cancer cell proliferation
- Mitochondrial dysfunction — Can induce oxidative stress selectively in cancer cells (in vitro)
- Autophagy modulation — May alter cellular recycling pathways leading to cell death
- MDR1 inhibition — Preclinical evidence of overcoming drug resistance mechanisms
Methylene Blue — Mitochondrial Targeting
- Electron carrier — Alters mitochondrial electron transport chain dynamics
- ROS generation — May increase reactive oxygen species selectively in cancer cells
- Autophagy induction — Preclinical data on triggering autophagic cell death pathways
- Photodynamic potential — Acts as photosensitizer under specific light wavelengths
Research Evidence by Compound
Honest assessment of where the science stands. Preclinical ≠ clinical. Animal data ≠ human proof.
Safety & Risk Assessment
There is NO human safety data for this combination of compounds. Each carries individual risks that may compound when stacked.
Fenbendazole, mebendazole, and methylene blue all carry hepatotoxicity risk. Stacking multiple hepatotoxic compounds significantly increases liver damage potential. Regular LFT (liver function tests) strongly recommended.
Multiple compounds metabolized via CYP enzymes. Cannabis oil inhibits CYP3A4/CYP2C9. This can alter blood levels of fenbendazole, mebendazole, ivermectin, and any concurrent medications unpredictably.
Amygdalin/B17 releases hydrogen cyanide during metabolism. Multiple deaths and poisonings documented. The FDA has banned its sale as a cancer treatment. This is the highest-risk compound in the stack.
Methylene blue is an MAO inhibitor. Combined with SSRIs, SNRIs, or other serotonergic drugs, it can trigger life-threatening serotonin syndrome. Contraindicated with many common antidepressants.
Activated charcoal binds indiscriminately — including medications and other protocol compounds. Must be taken 2+ hours away from all other substances. Can reduce effectiveness of concurrent cancer treatments.
Using unproven compounds instead of — or alongside — conventional cancer treatment can reduce treatment efficacy, cause dangerous interactions, or lead to treatment delays. Always involve your oncologist.
Community Protocol Variants
How different community versions of the protocol compare. None are clinically validated.
| Component | Original Tippens | Expanded Stack | Mebendazole Sub |
|---|---|---|---|
| Fenbendazole | 222mg, 3 on/4 off | 222mg, 3 on/4 off | — |
| Mebendazole | — | Optional add | 100–200mg daily |
| Curcumin | 600mg daily | 600mg daily | 600mg daily |
| CBD Oil | 25mg daily | Replaced by FECO | 25mg daily |
| Vitamin E (succinate) | 800 IU daily | 800 IU daily | 800 IU daily |
| Ivermectin | — | 0.2–0.4mg/kg, intermittent | Optional |
| Vitamin B17 | — | Varies (controversial) | — |
| FECO | — | Titrated to 1g/day | — |
| Methylene Blue | — | 0.5–1mg/kg | — |
| TUDCA | — | 250–500mg daily | 250–500mg daily |
| Activated Charcoal | — | 500–1000mg (timed) | Optional |
Key Study References
Primary research papers for each compound. Links go to PubMed/Nature for verification.
Key Takeaways
An honest look at what the evidence supports and what remains unknown.
✅ What We Know
- ✅ Fenbendazole shows multi-pathway anticancer activity in cell culture and animal models (Dogra 2018)
- ✅ Benzimidazoles (fenbendazole, mebendazole) disrupt microtubules similarly to some chemotherapy drugs
- ✅ Mebendazole has existing human safety data for antiparasitic use and limited case reports in cancer
- ✅ TUDCA has established hepatoprotective properties supported by clinical evidence
- ✅ Individual compounds have published preclinical anticancer data of varying quality
- ✅ Joe Tippens did achieve remission (though he was on concurrent immunotherapy)
⚠️ What We Don’t Know
- ⚠️ Whether any of these compounds work against cancer in humans at achievable doses
- ⚠️ Safety of combining 8 compounds with overlapping metabolic pathways
- ⚠️ Optimal dosing, cycling, or duration for any anticancer application
- ⚠️ How these compounds interact with standard cancer treatments (chemo, immunotherapy, radiation)
- ⚠️ Whether Tippens' remission was due to fenbendazole, immunotherapy, or spontaneous remission
- ⚠️ Long-term effects of benzimidazole use at these doses in humans
- ⚠️ Whether preclinical cancer cell kill translates to tumor reduction in living humans
Related Products
Commonly used supplies. Links go to Amazon search results. Inclusion does not constitute endorsement or medical recommendation.
Bacteriostatic Water
View on AmazonSharps Container
View on AmazonTUDCA Supplement
View on AmazonActivated Charcoal
View on AmazonCurcumin Supplement
View on AmazonDeep-Dive Into Each Compound
Detailed research guides for individual compounds in the protocol.
⚠️ Important Disclaimer
This page is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The Joe Tippens Protocol has not been validated in human clinical trials and is not endorsed by any medical organization or regulatory agency.
No compound described on this page is FDA-approved for cancer treatment (except mebendazole for parasitic infections). The protocol is based on one viral anecdote and preclinical (cell culture and animal) research that has not been replicated in controlled human studies.
Cancer is a life-threatening disease that requires professional medical treatment. Never replace or delay conventional cancer treatment based on information from this or any website. Always consult a qualified oncologist before making treatment decisions.
Dosages listed reflect community-shared protocols and are NOT medical recommendations. Individual responses vary. Many of these compounds carry significant risks including liver damage, drug interactions, and toxicity.
If you are currently undergoing cancer treatment, discuss any supplements or additional compounds with your oncology team before use.